Guess the CDIK news from a few days ago needed time to sink in for investors. I love this stock as an investment and for what it might do for my daughter who suffered an eye injury last year when a kid threw a rock which hit her eye. European and Asian sales soon and FDA approval around the corner - with a potential audience of 66.8 million people worldwide. I'll take it. I believe that this could hit $1.00 short term and $7-10 by years end with FDA Approval in place.
*********************************************************************************
HUGE NEWS- 100% SUCCESS RATE. Monday January 3, 8:04 am Eastern Time
Company Press Release
Coronado Industries' Medical Director Treats Patients in China With 100% Success Rate for Lowering IOP
FOUNTAIN HILLS, Ariz.--(BW HealthWire)--Jan. 3, 2000--Coronado Industries Inc. (OTC BB: CDIK - news; www.coronadoindustries.com) Monday announced that its medical director, Leo D. Bores, M.D., treated 29 glaucoma patients on a recent trip to Xian, China.
All of the patients treated experienced a lowering of intraocular pressure (IOP) as a result of treatment with Coronado's patented technology, pneumatic trabeculoplasty(TM) (PNT(TM)). Follow up with the patients since the treatment indicates that the IOP has remained lower as a result of the treatment.
Bores hosted a seminar on the PNT(TM) technology at a medical symposium in Xian Dec. 11, 1999. Everblooming Enterprises, a major distributor of ophthalmic devices in China, sponsored the trip. The Chinese Medical Association's Glaucoma team and top ophthalmologists from Beijing, Shanghai, and several other major provinces attended the seminar. Chinese National Television also broadcast a story on his visit and the technology. ''This is an important step toward introducing Coronado's PNT(TM) device into the healthcare community and major hospitals of China,'' said Gary Smith, president of Coronado Industries. ''The latest statistics show that 7 to 9 million people in China suffer from glaucoma and approximately 25 percent or 2 million are children.''
Bores also demonstrated the PNT(TM) technology for top Chinese military officials and was allowed unprecedented access at military bases in China. Based on the success of this first trip, Bores has been invited back to China in February. He is expected to visit major hospitals in Hong Kong and Singapore and conduct symposiums on glaucoma and the PNT(TM) technology for groups of physicians and other influential government officials. Bores' return trip will kick off Everblooming Enterprises' marketing campaign as a distributor of the PNT(TM) products in China. ''This can prove to be a valuable revenue stream for our company,'' said G. Richard Smith, CEO of Coronado industries.
Approximately 66.8 million people worldwide suffer from primary glaucoma according to a Johns Hopkins University School of Medicine study. Glaucoma is a progressive disease and is the second leading cause of blindness. More than 7.5 million Americans suffer from Glaucoma.
Glaucoma occurs when the optic nerve is damaged by high intraocular pressure (IOP). The optic nerve is responsible for sending impulses to the brain, which translates those signals into sight. When the nerve is damaged, the signals cease to be transmitted and loss of vision occurs. Currently, patients rely on eye drops or surgery to lower IOP. Coronado Industries' PNT(TM) technology is a non-invasive medical procedure that lessens, if not eliminates patients' dependence on drops without the risk and cost of surgery.
Applicable to open-angle and pigmentary glaucoma, the two most common types of glaucoma, PNT(TM) uses a suction device that is applied to the eye for 1 to 2 minutes. The treatment is proven safe and effective with no known side effects and is less costly than traditional therapies. Often one treatment is sufficient, but there is no risk in subsequent treatments if needed, as frequently as every three months. Evaluation of approximately four years of data from an ongoing study of patients receiving PNT(TM) has shown the procedure, originally designed to treat Primary Open Angle Glaucoma (POAG), pigmentary
glaucoma and glaucoma associated with pseudoexfoliation of the lens capsule, is of value in treating ocular hypertension, as well.
Safe Harbor Statement
The statements contained in this release which are not historical are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including, but not limited to, certain delays beyond the company's control with respect to market acceptance of new technologies and products, delays in testing and evaluation of products, and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission.
Coronado Industries, through its two wholly owned subsidiaries American Glaucoma and Ophthalmic International, manufactures devices to treat forms of glaucoma and offers glaucoma diagnosis and treatment under an I.D.E Study (Investigational Device Exemption). Pending FDA approval, Coronado will license its patented treatment procedure and
equipment in the United States. Coronado's Pneumatic Trabeculoplasty (PNT(TM)) procedure uses a non-invasive, patented, low-cost pneumatic device that has proven to be an effective and safe treatment option for glaucoma. In December 1998, Coronado was granted a CE Mark from the European Commission, which serves as a ''passport'' to allow a manufacturer to freely sell its products within the European Marketplace.
Contact:
Coronado Industries Inc., Fountain Hills
G. Richard Smith, 480/837-6810
or
Market Pathways
Shannon T. Squyres, 949/955-1860
More Quotes and News:
Coronado Industries Inc (OTC BB:CDIK.OB - news)
Related News Categories: health care, medical/pharmaceutical |
